This may render both TNF-α and adiponectin as appealing therapeutic targets in the setting of NAFLD-associated HCC, for which systemic immunotherapy, i.e., immune checkpoint inhibitors (ICIs), seems to be less effective compared to HCC of other etiologies. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.